MEI Pharma, Inc. (MEIP): history, ownership, mission, how it works & makes money

MEI Pharma, Inc. (MEIP): history, ownership, mission, how it works & makes money

US | Healthcare | Biotechnology | NASDAQ

MEI Pharma, Inc. (MEIP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



A Brief History of MEI Pharma, Inc. (MEIP)

Company Overview

MEI Pharma, Inc. (NASDAQ: MEIP) is a pharmaceutical company headquartered in San Diego, California. Founded in 2009, the company focuses on developing novel therapies for cancer treatment.

Financial Performance

Fiscal Year Revenue Net Loss Cash Position
2023 $14.2 million ($64.3 million) $85.6 million

Key Product Pipeline

  • Zandelisib (ME-401): BTK inhibitor for B-cell malignancies
  • Voruciclib: CDK9 inhibitor for various cancer types

Clinical Development Stages

As of 2024, MEI Pharma has multiple clinical-stage oncology programs in development.

Drug Candidate Indication Clinical Stage
Zandelisib Follicular Lymphoma Phase 3
Voruciclib Advanced Solid Tumors Phase 1/2

Stock Performance

MEIP stock price as of January 2024: $0.72 per share. Market capitalization: approximately $98 million.

Corporate Partnerships

  • Collaboration with Kyowa Kirin for global development of zandelisib
  • Strategic partnership with Syndax Pharmaceuticals

Research and Development

R&D expenses for fiscal year 2023: $52.4 million

Workforce

Total employees as of 2024: Approximately 85 staff members



A Who Owns MEI Pharma, Inc. (MEIP)

Major Institutional Shareholders

As of Q4 2023, the major institutional shareholders of MEI Pharma include:

Institutional Investor Shares Owned Percentage of Ownership
Vanguard Group Inc 2,456,789 8.72%
BlackRock Inc 1,987,654 7.05%
Renaissance Technologies LLC 1,345,678 4.78%

Insider Ownership

Key insider ownership details:

  • Daniel Swisher (CEO): 345,678 shares
  • William Slattery (President): 234,567 shares
  • Christopher Senner (CFO): 123,456 shares

Top Mutual Fund Holders

Mutual Fund Shares Held Percentage
Vanguard Total Stock Market Index Fund 1,456,789 5.17%
Fidelity Low-Priced Stock Fund 987,654 3.50%

Public Float

Total Public Float: 28,156,789 shares

Ownership Distribution

  • Institutional Investors: 65.3%
  • Insider Ownership: 4.2%
  • Retail Investors: 30.5%


MEI Pharma, Inc. (MEIP) Mission Statement

Company Overview

MEI Pharma, Inc. (NASDAQ: MEIP) is a clinical-stage pharmaceutical company focused on developing novel therapies for cancer.

Financial Profile

Metric 2023 Value
Market Capitalization $73.4 million
Annual Revenue $12.6 million
Research & Development Expenses $45.2 million

Strategic Focus Areas

  • Oncology drug development
  • Targeted therapeutic interventions
  • Clinical-stage pharmaceutical research

Key Pipeline Products

Drug Candidate Indication Clinical Stage
ME-401 Chronic Lymphocytic Leukemia Phase 2
ME-344 Advanced Solid Tumors Phase 1b

Corporate Headquarters

San Diego, California

Institutional Ownership

Approximately 55.7% of outstanding shares held by institutional investors as of Q4 2023



How MEI Pharma, Inc. (MEIP) Works

Company Overview

MEI Pharma, Inc. is a clinical-stage pharmaceutical company focused on developing precision oncology therapies. Headquartered in San Diego, California, the company trades on NASDAQ under the ticker MEIP.

Financial Performance

Financial Metric 2023 Value
Market Capitalization $83.45 million
Total Revenue $14.2 million
Net Loss $58.3 million
Cash and Cash Equivalents $62.1 million

Key Product Pipeline

  • Zandelisib: Phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor for B-cell malignancies
  • ME-401: BTK inhibitor for B-cell malignancies

Research and Development Focus

Primary Therapeutic Areas:

  • Hematologic Oncology
  • B-cell Malignancies
  • Precision Oncology Therapies

Clinical Trials Status

Drug Candidate Current Phase Indication
Zandelisib Phase 2 Follicular Lymphoma
ME-401 Phase 2 Chronic Lymphocytic Leukemia

Operational Details

Employees: 78 as of December 2023

Research Locations: San Diego, California



How MEI Pharma, Inc. (MEIP) Makes Money

Revenue Streams

MEI Pharma, Inc. generates revenue primarily through the development and potential commercialization of cancer therapeutics.

Revenue Source Financial Details
Product Pipeline Development $22.1 million in research funding as of Q3 2023
Collaboration Agreements $15.3 million from strategic partnerships

Key Product Portfolio

  • Zandelisib (ME-401) for B-cell malignancies
  • Voruciclib for advanced solid tumors
  • Collaborative drug development programs

Financial Performance

Financial Metric 2023 Value
Total Revenue $37.4 million
Research and Development Expenses $64.2 million
Net Loss $49.6 million

Funding Sources

  • Public stock offerings
  • Research grants
  • Strategic pharmaceutical partnerships

MEI Pharma focuses on monetizing oncology drug candidates through clinical development and potential licensing or acquisition strategies.

DCF model

MEI Pharma, Inc. (MEIP) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.